References
- World Health Assembly. Global eradication of poliomyelitis by the year 2000 (resolution 41.28). World Health Organization, Geneva, Switzerland (1988).
- World Health Organization. Transmission of wild poliovirus type 2: apparent global interruption. Wkly Epidemiol. Rec.76, 95–97 (2001).
- Duintjer Tebbens RJ, Pallansch MA, Cochi SL et al. Economic analysis of the global polio eradication initiative. Vaccine29(2), 334–343 (2011).
- Aylward RB, Acharya A, England S, Agocs M, Linkins J. Global health goals: lessons from the worldwide effort to eradicate poliomyelitis. Lancet362(9387), 909–914 (2003).
- Aylward RB, Yamada T. The polio endgame. N. Engl. J. Med.364, 2273–2275 (2011).
- Thompson KM, Duintjer Tebbens RJ, Pallansch MA et al. The risks, costs, and benefits of future global policies for managing polioviruses. Am. J. Pub. Health98(7), 1322–1330 (2008).
- Duintjer Tebbens RJ, Pallansch MA, Kew OM et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal.26(6), 1471–1505 (2006).
- Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Ann. Rev. Microbiol.59, 587–635 (2005).
- World Health Assembly. Poliomyelitis: mechanism for management of potential risks to eradication (resolution 61.1). World Health Organization, Geneva, Switzerland (2008).
- Flyvbjerg B, Buzelius N, Rothengatter W. Megaprojects and Risk. Cambridge University Press, Cambridge, UK (2003).
- Thompson KM, Duintjer Tebbens RJ. Using system dynamics to develop policies that matter: global management of poliomyelitis and beyond. Sys. Dynam. Rev.24(4), 433–449 (2008).
- Thompson KM, Duintjer Tebbens RJ. Economic evaluation of the benefits and costs of disease elimination and eradication initiatives. In: Disease Eradication in the 21st Century: Implications for Global Health. Cochi SL, Dowdle WR (Eds). MIT Press, Cambridge, MA, USA, 115–130 (2011).
- Thompson KM, Tebbens RJ. Eradication versus control for poliomyelitis: an economic analysis. Lancet369(9570), 1363–1371 (2007).
- Duintjer Tebbens RJ, Thompson KM. Priority shifting and the dynamics of managing eradicable infectious diseases. Manag. Sci.55(4), 650–663 (2009).
- Thompson KM. Variability and uncertainty meet risk management and risk communication. Risk Anal.22(3), 647–654 (2002).
- Thompson KM. Poliomyelitis and the role of risk analysis in global infectious disease policy and management. Risk Anal.26(6), 1419–1421 (2006).
- Thompson KM, Duintjer Tebbens RJ, Pallansch MA. Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Analys.26(6), 1541–1556 (2006).
- Thompson KM, Duintjer Tebbens RJ. Retrospective cost–effectiveness analyses for polio vaccination in the United States. Risk Anal.26(6), 1423–1440 (2006).
- Thompson KM, Wallace GS, Duintjer Tebbens RJ et al. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. Pub. Health Rep. (2012) (In Press).
- Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. Medscape J. Med.10(8), 190 (2008).